Current issues in reperfusion therapy

American Journal of Cardiology

Volumn 82, Issue 8 SUPPL. 1, 1998, Pages 3P-11P

  Gersh, Bernard J ^a,b  

^a GEORGETOWN UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ARGATROBAN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; HIRUDIN; HIRULOG; MAGNESIUM; NITRATE; THROMBIN INHIBITOR;

CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; FIBRINOLYTIC THERAPY; HEART INFARCTION; HEART MUSCLE REPERFUSION; HUMAN; HUMAN CELL; HUMAN TISSUE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; THROMBOSIS PREVENTION; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; PATIENT SELECTION; SURVIVAL ANALYSIS; THROMBOLYTIC THERAPY; TREATMENT OUTCOME;

EID: 0031786309     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00659-6     Document Type: Article

References (77)

1. Baumgarten W. Infarction in the heart. Am J Physiol 1899;2:243-265.
2. Reimer KA, Jennings RB. The wavefront phenomenon of myocardial ischemic cell death. II. Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow. Lab Invest 1979;40:633-644.
3. DeWood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, Lang HT. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980;303:897-902.
4. White HD, Van de Werf FJ. Thrombolysis for acute myocardial infarction. Circulation 1998;97:1632-1646.
5. Gersh BJ, Anderson JL. Thrombolysis and myocardial salvage. Results of clinical trials and the animal paradigm paradoxic or predictable? Circulation 1993;88:296-306.
6. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1998;ii:349-360.
7. Gruppo Italiano per lo Studio della Streptochinasi nell Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;i:397-402.
8. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997;337:1118-1123.
9. Wilcox RG, von der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton JR. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet 1988;ii:525-530.
10. Fibrinolytic Therapy Trialists (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet 1994;343:311-322.
11. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992;339:753-770.
12. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-682.
13. LATE Study Group. Late assessment of thrombolytic efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet 1993;342:759-766.
14. The ISAM Study Group. A prospective trial of intravenous streptokinase in acute myocardial infarction (ISAM): mortality, morbidity, and infarct size at 21 days. N Engl J Med 1986;314:1465-1471.
15. O'Keefe JH Jr, Sayed-Taha K, Gibson W, Christian TF, Batemen TM, Gibbons RJ. Do patients with left circumflex coronary artery-related acute myocardial infarction without ST-segment elevation benefit from reperfusion therapy? Am J Cardiol 1995;75:718-720.
16. The Multicenter Post infarction Research Group. Risk stratification and survival after myocardial infarction. N Engl J Med 1983;309:331-336.
17. Braunwald E. Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival. Should the paradigm be expanded? Circulation 1989;79:441-444.
18. Califf RM, Topol EJ, Gersh BJ. From myocardial salvage to patient salvage in acute myocardial infarction: the role of reperfusion therapy. J Am Coll Cardiol 1989;14:1382-1388.
19. Solomon A, Gersh BJ. The open-artery hypothesis. Annu Rev Med 1998;49:63-76.
20. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615-1622.
21. Nijland F, Kamp O, Verbeugt FW, Veen G, Visser CA. Long-term implications of reocclusion on left ventricular size and function after successful thrombolysis for first anterior myocardial infarction. Circulation 1997;95:111-117.
22. Lincoff AM, Topol EJ. Illusions of reperfusion. Does anyone achieve optimal reperfusion during acute myocardial infarction? Circulation 1993;88;1361-1374.
23. Keyt BA, Paoni NF, Refino CJ, Berleau L, Nguyen H, Chow A, Lai J, Peña L, Pater C, Ogez J, Etcheverry T, Botstein D, Bennett WF. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci USA 1994;91:3670-3674.
24. Larsen GR, Timony GA, Horgan PG, Barone KM, Henson KS, Angus LB, Stoudemire JB. Protein engineering of novel plasminogen activators with increased thrombolytic potency in rabbits relative to activase. J Biol Chem 1991;266:8156-8161.
25. Bär FW, Meyer J, Vermeer F, Michels R, Charbonnier B, Haerten K, Spiecker M, Macaya C, Hanssen M, Heras M, Boland JP, Morice MC, Dunn FG, Uebis R, Hamm C, Ayzenberg O, Strupp G, Withagen AJ, Klein W, Windeler J, Hopkins G, Barth H, von Fisenne MJ. Comparison of saruplase and alteplase in acute myocardial infarction. SESAM Study Group. The study in Europe with saruplase and alteplase in myocardial infarction. Am J Cardiol 1997;79:727-732.
26. Tebbe U, Michels R, Adgey J, Boland J, Caspi A, Charbonnier B, Windeler J, Barth H, Groves R, Hopkins GR, Fennell W, Betriu A, Ruda M, Mlczoch J. Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: the COMPASS Equivalence Trial. J Am Coll Cardiol 1998;31:487-493.
27. Every NR, Parsons LS, Hlatky M, Martin JS, Weaver WD. A comparison of thrombolytic therapy with primary coronary angioplasty for acute myocardial infarction. N Engl J Med 1996;335:1253-1260.
28. Ohnishi Y, Butterfield MC, Saffitz JE, Sobel BE, Corr PB, Goldstein JA. Deleterious effects of a systemic lytic state on reperfused myocardium. Minimization of reperfusion injury and enhanced recovery of myocardial function by direct angioplasty. Circulation 1995;92:500-510.
29. Weaver WD, Simes RJ, Betriu A, Grines CL, Zijlstra F, Garcia E, Grinfeld L, Gibbons RJ, Ribeiro EE, DeWood MA, Ribichini F. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA 1997;278;2093-2098.
30. Zijlstra F, de Boer MJ, Hoorntje JC, Reiffers S, Reiber JH, Suryapranata H. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 1993;328:680-684.
31. Ribeiro EE, Silva LA, Carneiro R, D'Oliveira LG, Gasquez A, Amino JG, Tavares JR, Petrizzo A, Torossian S, Duprat R, Buffolo E, Ellis SG. Randomized trial of direct coronary angioplasty versus intravenous streptokinase in acute myocardial infarction. J Am Coll Cardiol 1993;22:376-380.
32. Grinfeld L, Berrocal D, Belardi J, Spinetta A, Matas CR, Oberti P, Doval H, Bazzino O, Cagide A. Fibrinolytics vs primary angioplasty in acute myocardial infarction (FAP): a randomized trial in a community hospital in Argentina. (Abstr.) J Am Coll Cardiol 1996;27(suppl):222A.
33. Zijlstra F, Beukema WP, vant Hof AW, Liem A, Reiffers S, Hoorntje JC, Suryapranata H, de Boer MJ. Randomized comparison of primary coronary angioplasty with thrombolytic therapy in low risk patients with acute myocardial infarction. J Am Coll Cardiol 1997;29:908-912.
34. DeWood MA. Direct PTCA vs intravenous t-PA in acute myocardial infarction: results from a prospective randomized trial. Proceedings from the Thrombolysis and Interventional Therapy in Acute Myocardial Infarction Symposium VI. Washington, DC: George Washington University, 1990:28-29.
35. Grines CL, Browne KF, Marco J, Rothbaum D, Stone GW, O'Keefe J, Overlie P, Donohue B, Chelliah N, Timmis GC, Vlietstra RE, Strzelecki M, Puchrowicz-Ochocki S, O'Neill WW, for the Primary Angioplasty in Myocardial Infarction Study Group. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1993;328:673-679.
36. Gibbons RJ, Holmes DR, Reeder GS, Bailey KR, Hopfenspirger MR, Gersh BJ. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. N Engl J Med 1993;328:685-691.
37. Ribichini F, Steffenino G, Dellavalle A, Meinardi F, Vado A, Feola M, Uslenghi E. Primary angioplasty versus thrombolysis in inferior acute myocardial infarction with anterior ST-segment depression, a single-center randomized study. (Abstr.) J Am Coll Cardiol 1996;27(suppl):221A.
38. Garcia E, Elízaga J, Soriano J, Abeytua M, Botas J, Fernandéz A, Rubino R, Lopez E, Lopez-Sendón J, Delcán JL. Primary angioplasty versus thrombolysis with tPA in anterior myocardial infarction: results from a single center trial. (Abstr.) J Am Coll Cardiol 1997;29(suppl A):389A.
39. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1997;336:1621-1628.
40. Michels KB, Yusuf S. Does PTCA in acute myocardial infarction affect mortality and reinfarction rates? A quantitative overview (meta-analysis) of the randomized clinical trials. Circulation 1995;91:476-485.
41. Anderson JL, Karagounis LA, Muhlestein JB. Explaining discrepant mortality results between primary percutaneous transluminal coronary angioplasty and thrombolysis for acute myocardial infarction. Am J Cardiol 1996;78:934-939.
42. Every NR, Parsons LS, Hlatky M, Martin JS, Weaver WD. A comparison of thrombolytic therapy with primary angioplasty for acute myocardial infarction. N Engl J Med 1996;335:123-160.
43. Jollis JG, Peterson ED, Nelson CL, Stafford JA, DeLong ER, Muhlbaier LH, Mark DB. Relationship between physician and hospital coronary angioplasty volume and outcome in elderly patients. Circulation 1997;95:2485-2491.
44. Weaver WD, Cerqueira M, Hallstrom AP, Litwin PE, Martin JS, Kudenchuk PJ, Eisenberg M. Prehospital-initiated vs hospital-initiated thrombolytic therapy. The Myocardial Infarction Triage and Intervention Trial. JAMA 1993;270:1211-1216.
45. Doorey A, Patel S, Reese C, O'Connor R, Geloo N, Sutherland S, Price N, Gleasner E, Rodriguez R. Dangers of delay of initiation of either thrombolysis or primary angioplasty in acute myocardial infarction with increasing use of primary angioplasty. Am J Cardiol 1998;81:1173-1177.
46. Topol EJ. Toward a new frontier in myocardial reperfusion therapy. Emerging platelet preeminence. Circulation 1998;97:211-218.
47. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961.
48. Berger PB, Bell MR, Holmes DR Jr, Gersh BJ, Hopfenspirger M, Gibbons R. Time to reperfusion with direct coronary angioplasty and thrombolytic therapy in acute myocardial infarction. Am J Cardiol 1994;73:231-236.
49. Eisenberg PR, Sherman LA, Jaffe AS. Paradoxic elevation of fibrinopeptide A after streptokinase: evidence for continued thrombosis despite intense fibrinolysis. J Am Coll Cardiol 1987;10:527-529.
50. Meijer A, Verheugt FW, Werter CJ, Lie KI, van der Pol JM, van Eenige MJ. Aspirin versus coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: a prospective placebo-controlled angiographic study. Results of the APRICOT study. Circulation 1993;87:1524-1530.
51. Collins R, Peto R, Baigent C, Sleight P. Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med 1997;336:847-860.
52. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385-391.
53. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996;335:775-782.
54. Antman EM. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B Trial. Circulation 1996;94:911-921.
55. Neuhaus K-L, von Essen R, Tebbe U, Jessel A, Heinrichs H, Mäurer W, Döring W, Harmjanz D, Kötter V, Kalhammer E, Simon H, Horacek T. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK). Circulation 1994;90:1638-1642.
56. White HD, Aylward PE, Frey MJ, Adgey AAJ, Nair R, Hillis WS, Shalev Y, Brown MA, French JK, Collins R, Maraganore J, Adelman B. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation 1997;96:2155-2161.
57. Metz BK, White HD, Granger CB, Simes RJ, Armstrong PW, Hirsh J, Fuster V, MacAulay CM, Califf RM, Topol EJ. Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrolytic therapy for acute myocardial infarction: results from the GUSTO-IIb trial. J Am Coll Cardiol 1998;31:1493-1498.
58. Bittl JA, Strony J, Brinker JA, Ahmed WH, Meckel CR, Chaitman BR, Maraganore J, Deutsch E, Adelman B, for the Hirulog Angioplasty Study Investigators. Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 1995;333:764-769.
59. Théroux P, Fuster V. Acute coronary syndromes: unstable angina and non Q-wave myocardial infarction. Circulation 1998;97:1195-1206.
60. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335-371.
61. Roberts R, Rogers WJ, Mueller HS, Lambrew CT, Diver DJ, Smith HC, Willerson JT, Knatterud GL, Forman S, Passamani E, Zaret BL, Wackers FJT, Braunwald E, for the TIMI Investigators. Immediate versus deferred β-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B study. Circulation 1991;83:422-437.
62. Rogers WJ, Bowlby LJ, Chandra NC, French WJ, Gore JM, Lambrew CT, Rubison RM, Tiefenbrunn AJ, Weaver WD. Treatment of myocardial infarction in the United States (1990 to 1993). Observations from the National Registry of Myocardial Infarction. Circulation 1994;90:2103-2114.
63. Gruppo Italiano per lo Studio della Sopravvivenza nell Infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-1122.
64. ISIS-4 Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-685.
65. Dries DL, Solomon AJ, Gersh BJ. Adjunctive therapy after reperfusion therapy in acute myocardial infarction. Clin Cardiol 1998;21:379-386.
66. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-828.
67. Latini R, Maggioni AP, Flather M, Sleight P, Tognoni G. ACE inhibitor use in patients with myocardial infarction. Summary of evidence from clinical trials. Circulation 1995;92:3132-3137.
68. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction. Systematic overview of individual data from 100,000 patients in randomized trials. Circulation 1998;97:2202-2212.
69. Køber L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbæk J, Cole DS, Auclert L, Pauly NC, Aliot E, Persson S, Camm AJ, for the Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995;333:1670-1676.
70. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM, on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992;327:669-677.
71. Hall D, Zeitler H, Rudolph W. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol 1992;20:1549-1555.
72. Latini R. Aspirin does not interact with ACE inhibitors when both are given early after acute myocardial infarction. (Abstr.) J Am Coll Cardiol 1998;31(suppl A):310A.
73. Woods KL, Fletcher S, Roffe C, Haider Y. Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 1992;339:1553-1558.
74. Herzog WR, Schlossberg ML, MacMurdy KS, Edenbaum LR, Gerber MJ, Vogel RA, Serebruany VL. Timing of magnesium therapy affects experimental infarct size. Circulation 1995;92:2622-2626.
75. Rabbani LE, Antman EM. The role of magnesium therapy in acute myocardial infarction. Clin Cardiol 1996;19:841-844.
76. Yusuf S, Furberg CD. Effects of calcium channel blockers on survival after myocardial infarction. Cardiovasc Drugs Ther 1987;1:343-344.
77. The Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II - DAVIT II). Am J Cardiol 1990;66:779-785.